ARCHIVES

As patients worry about COX-2 inhibitors, scientists and FDA review toxicity data.

This article is from The Cancer Letter archive.

Vol. 30 No. 40 | October 22, 2004

Download PDF Visit The Full Archive

Related Articles

Clinical Trials Approved By NCI CTEP Last Month

April 29, 2011

Henles to Get Bristol-Myers $25,000 Award

March 23, 1979

CCOPs At Six Months: Sme Exceeding Patient Goals, Most Are Meeting Schedules

March 30, 1984

SWOG Closes Prostate Cancer Trial With Mitoxantrone

February 23, 2007

NCI Faced Pressure From Congress, HHS, White On Mammography Statement

April 11, 1997

Bishop: Cells, Genes Reveal Unified Strategy For Cancer Conquest

March 3, 1995